Login
Israel-Hamas Conflict
Independence Day
Social Media
Wrestling
Floods
Formula 1
Natural Disasters
World Cup
Donald Trump
Cryptocurrency
Tennis
Property
Amazon
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

ophthalmologytimes.com image

News from ophthalmologytimes.com

We’ve assigned a media bias rating of unknown to ophthalmologytimes.com. You can read more about our methodology here.

Information about ophthalmologytimes.com

Where is ophthalmologytimes.com located?ophthalmologytimes.com's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ophthalmologytimes.com News

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
Palo Alto · Palo Alto

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

87% Center coverage: 15 sources
PALO ALTO, Calif., June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management along with key opinion…See the Story
Biocon's Breakthrough: Yesafili Gets Green Light in Canada
Health Canada · Toronto

Biocon's Breakthrough: Yesafili Gets Green Light in Canada

67% Left coverage: 9 sources
Biocon Biologics has received Health Canada's approval for Yesafili, a biosimilar injection for eye ailments. As the first Eylea biosimilar approved in Canada, Yesafili's launch is set for July 4, 2025. This milestone highlights Biocon's commitment to affordable, high-quality biologics worldwide.See the Story
Apotex Receives Health Canada Approval for Aflivu™, a Biosimilar to Eylea®, Available in Pre-Filled Syringe and Vial Formats
Health Canada · Toronto

Apotex Receives Health Canada Approval for Aflivu™, a Biosimilar to Eylea®, Available in Pre-Filled Syringe and Vial Formats

72% Center coverage: 7 sources
TORONTO, July 2, 2025 /PRNewswire/ - Apotex Inc. ("Apotex" or the "Company"), the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration,…See the Story

Startup That Makes Robots For Cataract Surgery Raises $125 Million In Second-Largest Fundraise For A Surgical Robotics Firm

100% Center coverage: 2 sources
Millions of people get cataract surgery every year. What if a robot could do it better than humans?See the Story

Exposure to pesticides and increased risk of AMD

A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.AMDRead Article

Beacon Therapeutics exercises option to license Abeona Therapeutics’ AAV204 capsid

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.Chapel Hill, North Carolina · Chapel HillRead Article

From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what “controlled” really means.Maryland · MarylandRead Article

Yale researchers identify corneal ulcer pathogens by testing tears

A new study demonstrates that handheld nanopore sequencers can rapidly identify eye infection pathogens using only a patient’s tears.Yale · New HavenRead Article

HLB Therapeutics misses primary endpoint in phase 3 SEER-3 trial of RGN-259

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop to treat people with neurotrophic keratitis.Read Article

Prevent Blindness Declares July as Dry Eye Month

In addition to Prevent Blindness’s usual free resources, the organization is providing a dedicated webpage, fact sheets, and graphics in both English and Spanish.See the Story

Sanaregen Vision Therapeutics Invites Prospective Investors to Reserve Stock Shares

Sanaregen Vision Therapeutics invites investors to reserve shares as it prepares for an equity crowdfunding campaign to advance retinal disease treatments.See the Story

Breaking News Topics Related to ophthalmologytimes.com

Utah icon

Utah

AMD icon

AMD

Salt Lake County icon

Salt Lake County

Maryland icon

Maryland

Salt Lake City icon

Salt Lake City

United States icon

United States

News
For You
SearchBlindspotLocal